(Q37794772)

23 August 2017

title

Therapeutic potential of oncolytic measles virus: promises and challenges (English)

1 reference

23 August 2017

Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges (English)

1 reference

DOI

10.1038/CLPT.2010.211

https://api.crossref.org/works/10.1038/CLPT.2010.211

23 July 2024

1 reference

1 reference

E. Galanis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20881957

23 July 2024

language of work or name

English

0 references

publication date

29 September 2010

1 reference

Clinical Pharmacology & Therapeutics

23 August 2017

published in

1 reference

23 August 2017

volume

88

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

620-625

1 reference

Successes and failures in measles control

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

Regression of Burkitt's lymphoma in association with measles infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Possible effect of measles on leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Regression of Hodgkin's disease after measles

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

SLAM (CDw150) is a cellular receptor for measles virus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Engineered measles virus as a novel oncolytic therapy against prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Antibody-targeted cell fusion

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Rescue and propagation of fully retargeted oncolytic measles viruses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Affinity thresholds for membrane fusion triggering by viral glycoproteins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Oncolytic measles virus strains in the treatment of gliomas

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Biodistribution of Oncolytic Measles Virus After Intraperitoneal Administration into Ifnar™-CD46Ge Transgenic Mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Heat shock protein inhibitors increase the efficacy of measles virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.211

7 January 2021

Measles virus spread and pathogenesis in genetically modified mice

series ordinal

35

1 reference

DOI

10.1038/CLPT.2010.211

https://api.crossref.org/works/10.1038/CLPT.2010.211

23 July 2024

Identifiers

DOI

10.1038/CLPT.2010.211

1 reference

23 August 2017

1 reference